2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2112

Disease-Activity Associated Autoantibodies to Malondialdehyde-Modified Proteins Can be Isolated from Synovial B Cells in RA
Abstract Number: 2113

Anti-Carbamylated Protein Antibody (cross)-Reactivity Against Multiple Carbamylated Protein Antigens
Abstract Number: 2114

Exposure to Carbamylated Self- and Non-Self-Proteins Can Lead to a Break-of -Tolerance and the Induction of Autoimmunity
Abstract Number: 2115

Rheumatoid Factors May Potentiate Immune Complex Formation of Anti-Citrullinated Protein Antibodies
Abstract Number: 2116

Cytokines Inhibition Modulates Activation and Homing Receptor of Different Peripheral Memory B Cell Subsets in RA
Abstract Number: 2117

B Cell Phenotype and in Vitro Function in Patients with Rheumatoid Arthritis Developing Low Serum Immunoglobulins after Multiple Cycles of Rituximab
Abstract Number: 2118

Rituximab Treated Non Responder Rheumatoid Arthritis Patients Are Generating a New Autoantibody Repertoire
Abstract Number: 2119

Wogonin, a Plant-Derived Flavonoid, Exert Anti-Inflammatory and Chondroprotective Effects through the Activation Nrf2/HO-1 Signaling in Human OA Chondrocytes
Abstract Number: 2120

Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) As a Potential Treatment for Degenerative Disc Disease
Abstract Number: 2121

Identification of microRNA-181a-5p and microRNA-4454 As Mediators of Facet Cartilage Degeneration
Abstract Number: 2122

KiSS1 Is a Regulator of ADAMTS4 and ADAMTS5 Expression and Is Post-Transcriptionally Regulated By Micro-RNA N105 in Human OA Chondrocytes
Abstract Number: 2123

Follistatin-like Protein 1 Is a Potent Regulator of Articular Chondrocytes in Osteoarthritis
Abstract Number: 2124

Maintenance of Chondrocyte Phenotypic Stability By TRPC6 Calcium Channel Activity
Abstract Number: 2125

Aggrecan Degradation Is Not Just Aggrecan Degradation:a Study of the Neo-Epitopes Tege and Args Released from Cartilage upon Aggrecanase Activity
Abstract Number: 2126

Cytokine Dependent Effects of Anti-Inflammatory Inhibitors Targeting JAK and p38 on Cartilage Turnover

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].